TY - JOUR
T1 - Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 1994
T2 - PHARMACODYNAMICS OF LEVODOPA IN PARKINSON'S DISEASE
AU - Nutt, J. G.
PY - 1995/11
Y1 - 1995/11
N2 - 1. Levodopa markedly reduces parkinsonism during the first years of treatment. However, with continued therapy the response to levodopa becomes erratic and is complicated by involuntary movements. To improve the therapy of parkinsonism, the challenge is to understand why fluctuations in response develop and, once developed, what controls the moment to moment motor status. 2. In patients with a fluctuating response to levodopa, three distinct responses can be recognized: a short‐duration response, a long‐duration response and a negative response. 3. The short‐duration response, measured in minutes to hours, has a steep concentration‐response relationship such that the response appears ‘all or nothing.’ The duration of effect is dose‐responsive. The short‐duration response becomes shorter during chronic therapy, possibly because of tolerance. The onset to effect becomes briefer and the magnitude of the response becomes larger during chronic therapy, possibly because of sensitization. 4. The long‐duration response, measured in days to weeks, develops and decays slowly. The rate of decay is proportional to the severity of the parkinsonism and therefore this response may relate to dopamine storage capacity of remaining nerve terminals. 5. The negative response, measured in minutes, is a worsening of motor function as the short‐duration improvement wears off. It may reflect a biphasic concentration‐response relationship. 6. The response to levodopa in parkinsonian patients is a complex interplay between responses with different time courses and variably affected by sensitization, tolerance and disease progression.
AB - 1. Levodopa markedly reduces parkinsonism during the first years of treatment. However, with continued therapy the response to levodopa becomes erratic and is complicated by involuntary movements. To improve the therapy of parkinsonism, the challenge is to understand why fluctuations in response develop and, once developed, what controls the moment to moment motor status. 2. In patients with a fluctuating response to levodopa, three distinct responses can be recognized: a short‐duration response, a long‐duration response and a negative response. 3. The short‐duration response, measured in minutes to hours, has a steep concentration‐response relationship such that the response appears ‘all or nothing.’ The duration of effect is dose‐responsive. The short‐duration response becomes shorter during chronic therapy, possibly because of tolerance. The onset to effect becomes briefer and the magnitude of the response becomes larger during chronic therapy, possibly because of sensitization. 4. The long‐duration response, measured in days to weeks, develops and decays slowly. The rate of decay is proportional to the severity of the parkinsonism and therefore this response may relate to dopamine storage capacity of remaining nerve terminals. 5. The negative response, measured in minutes, is a worsening of motor function as the short‐duration improvement wears off. It may reflect a biphasic concentration‐response relationship. 6. The response to levodopa in parkinsonian patients is a complex interplay between responses with different time courses and variably affected by sensitization, tolerance and disease progression.
KW - Parkinson's disease
KW - levodopa
KW - pharmacodynamics.
UR - http://www.scopus.com/inward/record.url?scp=0028874630&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028874630&partnerID=8YFLogxK
U2 - 10.1111/j.1440-1681.1995.tb01946.x
DO - 10.1111/j.1440-1681.1995.tb01946.x
M3 - Article
C2 - 8593740
AN - SCOPUS:0028874630
SN - 0305-1870
VL - 22
SP - 837
EP - 840
JO - Clinical and Experimental Pharmacology and Physiology
JF - Clinical and Experimental Pharmacology and Physiology
IS - 11
ER -